Clinical Trials

Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer

Location:

Jacksonville,  FL,  Scottsdale and Phoenix,  AZ,  Rochester,  MN

Trial status:

Open for Enrollment

Why is this study being done?

OBJECTIVES:

- To determine the maximum tolerated dose of gold sodium thiomalate in patients with advanced non-small cell lung cancer.

- To describe the toxicities associated with this treatment.

- To describe any preliminary evidence of biologic activity.

- To further assess the correlation between PKCι expression and the antitumor effects of gold sodium thiomalate.

- To study the association of clinical (toxicity and/or tumor response or activity) with pharmacokinetic/pharmacodynamic parameters.

- To describe anti-proliferative activity of gold sodium thiomalate through 3-deoxy-3-[^18F]-fluorothymidine positron emission tomography imaging.

OUTLINE: This is a dose-escalation study of gold sodium thiomalate.

Patients receive gold sodium thiomalate intramuscularly on days 1, 8, 15 and 22. Treatment repeats every 4 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive gold sodium thiomalate once every 4 weeks until a total cumulative dose of 1 gram is delivered.

Blood samples are collected at baseline and prior to therapy in weeks 3, 5, 7, 9, and 11. Samples are analyzed by mass spectometry for pharmacokinetics. Paraffin-embedded tumor tissue samples are analyzed for PKC_l expression and antitumor activity. Antiproliferative effects of gold sodium thiomalate are analyzed by 3-deoxy-3-[^18F]-fluorothymidine positron emission tomography imaging.

Who is eligible to participate?

DISEASE CHARACTERISTICS:

- Histologically confirmed advanced non-small cell lung cancer

- No known standard therapy for disease that is potentially curative or definitely capable of extending life expectancy

- No symptomatic or worsening CNS metastases despite optimal therapy

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy ≥ 12 weeks

- ANC ≥ 1,500/µL

- Platelet count ≥ 100,000/µL

- Total bilirubin ≤ 2 times upper limit of normal (ULN)

- AST ≤ 3 times ULN (5 times ULN if liver involvement)

- Creatinine ≤ 1.2 times ULN

- Hemoglobin ≥ 9.0 g/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Must be willing to provide blood and tissue samples

- No uncontrolled infection

- No New York Heart Association class III or IV heart disease

- No known allergy to gold sodium thiomalate

PRIOR CONCURRENT THERAPY:

- Recovered from acute, reversible effects of prior chemotherapy regardless of interval since last treatment

- No prior chemotherapy within the past 3 weeks

- No prior mitomycin C or nitrosoureas within the past 6 weeks

- No prior immunotherapy within the past 3 weeks

- No prior biologic therapy within the past 3 weeks

- No prior radiotherapy within the past 3 weeks

- No prior radiotherapy to > 25% of bone marrow

- No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (i.e., utilized for a non-FDA-approved indication and in the context of a research investigation)

- No concurrent prophylactic colony stimulating factors

Last updated: 03/26/2012

NCT ID:

NCT00575393